EUSA Pharma Signs Exclusive Distribution Agreement With Samaritan for Anesthetic Pain Patch
January 03, 2008
Jan 04, 2008 -- /prbuzz/ --Rapydan Boosts Sales Arm Pipeline to Eleven Revenue Generating Specialty Products

Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce that it has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus.

Rapydan provides a Controlled Heat-Assisted Drug Delivery (CHADD) technology that allows for the targeted, rapid and deep anesthetic effect of Lidocaine and Tetracaine. The topically administered patch contains a heating element that warms the surface temperature of the skin instigating a vasodilatory effect; consequently, two major benefits are observed: the rapid onset of anesthesia and the increased accessibility of blood vessels.

Rapydan is indicated for surface anesthesia of the skin in connection with needle puncture in adults and children, and in cases of superficial surgical procedures on normal intact skin in adults.

Visit the RAPYDAN website: www.rapydan.net

Visit List of In-licensed Products: http://www.samaritanpharma.com/marketed_products.asp

Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210

Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
EUSA Pharma Signs Exclusive Distribution Agreement With Samaritan for Anesthetic Pain Patch

About the Press Release
Samaritan has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. Rapydan Boosts Sales Pipeline to 11 drugs.


 
< Prev   Next >